JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Anti-Lipogenic Effect of Functional Cereal Samples on High Sucrose Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Anti-Lipogenic Effect of Functional Cereal Samples on High Sucrose Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice
Lee, Ko-Eun; Song, Jia-Le; Jeong, Byung-Jin; Jeong, Jong-Sung; Huh, Tae-Gon; Park, Kun-Young;
  PDF(new window)
 Abstract
The anti-lipogenic effect of cereal samples on high sucrose diet (HSD)-induced non-alcoholic fatty liver disease (NAFLD) in mice was studied. We divided C57BL/6 mice into various groups based on 8 weeks of treatment with three types of cereal samples (HSD+WR, HSD diet containing 40% white rice; HSD+MCG, HSD diet containing 40% mixed cereal grain; HSD+AO-MCG, HSD diet containing 40% mixed antiobesity-cereal grain). After the experimental period, body weight changes, liver weights, serum lipid profiles, and hepatic fatty acid metabolism-related gene expression levels were determined. We found that HSD+WR, HSD+MCG, and HSD+AO-MCG treatments reduced body weight and liver weight, especially HSD+MCG and HSD+AO-MCG effectively reduced levels of serum triglycerides, total cholesterol, and low-density lipoprotein cholesterol. However, high density lipoprotein cholesterol levels increased compared to the control group. Furthermore, expression of hepatic lipogenic genes such as sterol regulatory element-binding protein-1c, acetyl-coenzyme A carboxylase, fatty acid synthase, stearoyl-coenzyme A desaturase-1, cluster of differentiation, and (peroxisome proliferator activated receptor ) decreased, whereas expression of genes such as and carnitine palmitoyl transferase-1 increased following HSD+MCG and HSD+AO-MCG treatment compared with levels in HSD+WR and control groups. These results suggest that the functional cereal samples, especially HSD+AO-MCG treatment, improved hepatic steatosis triggered by an HSD-induced imbalance in hepatic lipid metabolism.
 Keywords
mixed cereal grains;non-alcoholic fatty liver disease;steatosis;high sucrose diet;
 Language
Korean
 Cited by
 References
1.
Vernon G, Baranova A, Younossi ZM. 2011. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34: 274-285. crossref(new window)

2.
Bae JC, Cho YK, Lee WY, Seo HI, Rhee EJ, Park SE, Park CY, Oh KW, Sung KC, Kim BI. 2010. Impact of nonalcoholic fatty liver disease on insulin resistance in relation to HbA1c levels in nondiabetic subjects. Am J Gastroenterol 105: 2389-2395. crossref(new window)

3.
Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. 2012. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55: 2005-2023. crossref(new window)

4.
Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N. 2001. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50: 1844-1850. crossref(new window)

5.
Cohen JC, Horton JD, Hobbs HH. 2011. Human fatty liver disease: old questions and new insights. Science 332: 1519-1523. crossref(new window)

6.
Musso G, Gambino R, Cassader M. 2009. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res 48: 1-26. crossref(new window)

7.
Kang M, Joung H, Lim JH, Lee YS, Song YJ. 2011. Secular trend in dietary patterns in a Korean adult population, using the 1998, 2001, and 2005 Korean National Health and Nutrition Examination Survey. Korean J Nutr 44: 152-161. crossref(new window)

8.
Ministry of Health and Welfare, Korean Centers for Disease Control and Prevention. 2012. Korea health statistics 2011: Korean national health and nutrition examination survey (KNHANES V-2). Ministry of Health and Welfare, Sejong, Korea. p 37-46.

9.
Song S, Lee JE, Song WO, Paik HY, Song Y. 2014. Carbohydrate intake and refined-grain consumption are associated with metabolic syndrome in the Korean adult population. J Acad Nutr Diet 114: 54-62. crossref(new window)

10.
Barclay AW, Petocz P, McMillan-Price J, Flood VM, Prvan T, Mitchell P, Brand-Miller JC. 2008. Glycemic index, glycemic load, and chronic disease risk - a meta-analysis of observational studies. Am J Clin Nutr 87: 627-637.

11.
Jung YJ, Cho YJ, Kim KW, Yoon KY. 2013. Current status and development plan of domestic cereal industry. Food Preservation and Processing Industry 12(1): 31-39.

12.
Madar Z. 1983. Effect of brown rice and soybean dietary fiber on the control of glucose and lipid metabolism in diabetic rats. Am J Clin Nutr 38: 388-393.

13.
Newman RK, Lewis SE, Newman CW, Boik RJ, Ramage RT. 1989. Hypocholesterolemic effect of barley foods on healthy men. Nutr Rep Int 39: 749-760.

14.
Sin MK, Han SH. 2001. Effects of methanol extracts from Phaseolus vulgaris on serum lipid concentrations in rats fed high fat and cholesterol diet. Korean J Food Sci Technol 33: 113-116.

15.
Kim JM, Park JY, Kim KW, Yoon KY. 2014. Nutritional composition and functionality of mixed cereals powder. Korean J Food Preserv 21: 388-395. crossref(new window)

16.
Rawson RB. 2003. Control of lipid metabolism by regulated intramembrane proteolysis of sterol regulatory element binding proteins (SREBPs). Biochem Soc Symp 70: 221-231.

17.
Hashimoto T, Cook WS, Qi C, Yeldandi AV, Reddy JK, Rao MS. 2000. Defect in peroxisome proliferator-activated receptor ${\alpha}$-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting. J Biol Chem 275: 28918-28928. crossref(new window)

18.
Lapsys NM, Kriketos AD, Lim-Fraser M, Poynten AM, Lowy A, Furler SM, Chisholm DJ, Cooney GJ. 2000. Expression of genes involved in lipid metabolism correlate with peroxisome proliferator-activated receptor ${\gamma}$ expression in human skeletal muscle. J Clin Endocrinol Metab 85: 4293-4297.

19.
Koteish A, Mae Diehl A. 2002 Animal models of steatohepatitis. Best Pract Res Clin Gastroenterol 16: 679-690. crossref(new window)

20.
Spruss A, Kanuri G, Wagnerberger S, Haub S, Bischoff SC, Bergheim I. 2009. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 50: 1094-1104. crossref(new window)

21.
Ha J. 2002. Analysis of volatile organic compounds in kimchi absorbed in SPME by GC-AED and GC-MSD. J Korean Soc Food Sci Nutr 31: 543-545. crossref(new window)

22.
Jansson EA, Are A, Greicius G, Kuo IC, Kelly D, Arulampalam V, Pettersson S. 2005. The Wnt/${\beta}$-catenin signaling pathway targets $PPAR{\gamma}$ activity in colon cancer cells. Proc Natl Acad Sci USA 102: 1460-1465. crossref(new window)

23.
Park MY, Jang HH, Lee JY, Lee YM, Kim JH, Park JH, Park DS. 2012. Effect of hog millet supplementation on hepatic steatosis and insulin resistance in mice fed a high-fat diet. J Korean Soc Food Sci Nutr 41: 501-509. crossref(new window)

24.
Kim SR, Seog HM, Choi HD, Park YK. 2002. Cholesterollowering effects in rat liver fed barley and ${\beta}$-glucan-enriched barley fraction with cholesterol. Korean J Food Sci Technol 34: 319-324.

25.
Ho JN, Son ME, Lim WC, Lim ST, Cho HY. 2012. Antiobesity effects of germinated brown rice extract through down-regulation of lipogenic genes in high fat diet-induced obese mice. Biosci Biotechnol Biochem 76: 1068-1074. crossref(new window)

26.
Rabey HAE, Al-Seeni MN, Amer HM. 2013. Efficiency of barley bran and oat bran in ameliorating blood lipid profile and the adverse histological changes in hypercholesterolemic male rats. BioMed Res Int 2013: 263594.

27.
Postic C, Girard J. 2008. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 118: 829-838. crossref(new window)

28.
Gervois P, Torra IP, Fruchart JC, Staels B. 2000. Regulation of lipid and lipoprotein metabolism by PPAR activators. Clin Chem Lab Med 38: 3-11.